Max Healthcare Institute Intrinsic Value
MAXHEALTH Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹310.41 | ₹248.33 - ₹372.49 | -70.0% | EPS: ₹20.20, Sector P/E: 12x |
| Book Value Method | asset | ₹206.94 | ₹186.25 - ₹227.63 | -80.0% | Book Value/Share: ₹96.51, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹310.41 | ₹279.37 - ₹341.45 | -70.0% | Revenue/Share: ₹89.22, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹413.88 | ₹372.49 - ₹455.27 | -60.0% | EBITDA: ₹2432.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹413.88 | ₹331.10 - ₹496.66 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹310.41 | ₹279.37 - ₹341.45 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹310.41 | ₹279.37 - ₹341.45 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹517.35 | ₹465.62 - ₹569.09 | -50.0% | ROE: 20.9%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹310.41 | ₹279.37 - ₹341.45 | -70.0% | EPS: ₹20.20, BVPS: ₹96.51 |
Want to compare with current market value? Check MAXHEALTH share price latest .
Valuation Comparison Chart
MAXHEALTH Intrinsic Value Analysis
What is the intrinsic value of MAXHEALTH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Max Healthcare Institute (MAXHEALTH) is ₹310.41 (median value). With the current market price of ₹1034.70, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹206.94 to ₹517.35, indicating ₹206.94 - ₹517.35.
Is MAXHEALTH undervalued or overvalued?
Based on our multi-method analysis, Max Healthcare Institute (MAXHEALTH) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.40 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.62 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 20.9% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 27.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.57x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Max Healthcare Institute
Additional stock information and data for MAXHEALTH
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,459 Cr | ₹652 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹1,122 Cr | ₹496 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹1,284 Cr | ₹1,233 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹749 Cr | ₹363 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹118 Cr | ₹118 Cr | Positive Free Cash Flow | 8/10 |